COSTEM 2023 | Bispecific antibodies vs CAR-T cells in DLBCL: the benefit of CAR-T therapy
Michael Bishop, MD, University of Chicago, Chicago, IL, discusses a debate held at this year’s meeting which focused on the use of CAR-T cells versus bispecific antibodies in the treatment of diffuse large B-cell lymphoma (DLBCL), highlighting the higher efficacy and rates of complete remission (CR) observed with CAR-T cells. This interview took place at The 8th Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM 2023), held in Berlin, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Membership on a Advisory Board or Consultant: KITE/Gilead, Novartis, CRISPR Therapeutics, Autolus Therapeutics, BMS/JUNO Therapeutics, Incyte, Sana Biotechnology, Iovance Biotherapeutics, In8bio, Chimeric Therapeutics
Speakers Bureau: BMS, Kite/Gilead, Servier, AstraZeneca, ADC Therapeutics, Incyte
